Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US07725L1026
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00B6WF7T5
ONC
BeOne Medicines Ltd.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
BeOne Medicines Ltd.
ISIN
US07725L1026
TICKER
ONC
MIC
XNAS
REUTERS
ONC.OQ
BLOOMBERG
ONC US
Di., 27.05.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitab...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 22.05.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. W...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors sect...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth....
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) tha...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 17.04.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee r...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 31.03.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with et...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 04.03.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresecta...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 27.02.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 25.02.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and Leerink Par...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 13.02.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 06.01.2025       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment will enhance the Company’s commitment to bring impactful medicines to mor...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Fr., 27.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unre...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 23.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, changin...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Fr., 13.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhi...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 10.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 04.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the world’s leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cancer patients. Together, they are advancing Test...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 27.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesop...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 26.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi’s Global Healthcare...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       BeOne Medicines
US07725L1026

Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang wil...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA)...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112799807/en/(Graphic: Business Wire) “Our exceptional third-quar...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies London Healthcare Conference on November 20, 2024, with a fireside chat at 2:30 p.m. GMT. The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com, h...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 05.11.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the pas...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 21.10.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab) in gastric or gastroesophageal junction (G/GEJ) adenocarcinom...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 16.10.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA® (zanubrutinib), Bruton tyrosine kinase (BTK) chimeric degradation activation compound (CDAC) degrader BGB-16673 and B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in patients with Waldenström’s...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Fr., 27.09.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recognizes the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of patients with locally advanced...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Do., 26.09.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024. “We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth,” said John V. O...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Di., 17.09.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or metastatic oesophageal squamous cell carcinoma (OESCC) after prior systemic chemotherapy. "In...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Fr., 13.09.2024       BeOne Medicines
US07725L1026

SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). Lymphoma, a type of blood cancer affecting millions of people worldwide, is the focus of WLAD, which serves a...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 09.09.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. “We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 09.09.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://i...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink
Mo., 26.08.2024       BeOne Medicines
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an orally available investigational Bruton’s tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC), for adult patients with re...
Zur Nachricht
BeOne Medicines
Charts & Research Termsheets Terminal
Permalink